Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Noelle Jung, Thorben Hennig, Leo Ruhnke, Joris Maximillian Frenz, Maithreyan Kuppusamy, Robert Autry, Lanying Wei, Kaiyan Sun, Helal Mohammed Mohammed Ahmed, Axel Künstner, Hauke Busch, Heiko Müller, Stephan Hutter, Gregor Hoermann, Longlong Liu, Xiaoqing Xie, Yahya Al-Matary, Subbaiah Chary Nimmagadda, Fiorella Charles Cano, Michael Heuser, Felicitas Thol, Gudrun Göhring, Doris Steinemann, Jürgen Thomale, Theo Leitner, Anja Fischer, Roland Rad, Christoph Röllig, Heidi Altmann, Desiree Kunadt, Wolfgang E. Berdel, Jana Hüve, Felix Neumann, Jürgen Klingauf, Virginie Calderon, Bertram Opalka, Ulrich Dührsen, Frank Rosenbauer, Martin Dugas, Julian Varghese, Hans Christian Reinhardt, Nikolas von Bubnoff, Tarik Möröy, Georg Lenz, Aarif M. N. Batcha, Marianna Giorgi, Murugan Selvam, Eunice Wang, Shannon K. McWeeney, Jeffrey W. Tyner, Friedrich Stölzel, Matthias Mann, Ashok Kumar Jayavelu, Cyrus Khandanpour

Blood (2023) 142 (25): 2175–2191.

https://doi.org/10.1182/blood.2022015752

Published: 2023

Includes: Supplemental data

Journal Articles

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Subbaiah Chary Nimmagadda, Pradeep Kumar Patnana, Paulina Marie Budde, Helal Ahmed, Todd Covey, Cecile Krejsa, Wayne Rothbaum, Nikolas Von Bubnoff, Cyrus Khandanpour

Blood (2023) 142 (Supplement 1): 2782.

https://doi.org/10.1182/blood-2023-174895

Published: 2023

Journal Articles

Liquid Biopsy Enhances Diagnostic Workup of Hereditary Alpha-Tryptasemia (HaT) and Systemic Mastocytosis (SM) in Patients with Mast Cell-Mediated Symptoms and Elevated Basal Tryptase Levels

Daniel Koch, Hannah Stocker, Friederike Wortmann, Franziska Axt, Cyrus Khandanpour, Eva Dazert, Christian Sina, Dagmar von Bubnoff, Nikolas Von Bubnoff

Blood (2023) 142 (Supplement 1): 2546.

https://doi.org/10.1182/blood-2023-188962

Published: 2023

Journal Articles

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2023) 142 (Supplement 1): 619.

https://doi.org/10.1182/blood-2023-173225

Published: 2023

Journal Articles

Virtual Reality-Assisted Exercise Therapy during Inpatient Treatment after Intensive Chemotherapy for Acute Myeloid Leukemia (AML) and after Autologous or Allogeneic Stem Cell Transplantation

Friederike Wortmann, Philipp Koch, Cyrus Khandanpour, Nikolas Von Bubnoff

Blood (2023) 142 (Supplement 1): 5091.

https://doi.org/10.1182/blood-2023-174677

Published: 2023

Journal Articles

Mutational Changes in Solid Cancer Cells Induce DNA Damage Repair Deficiency in Hematopoietic Cells Leading to a Distinct Spectrum of Clonal Hematopoiesis Independent from Age-Related Clonal Hematopoiesis

Theo Leitner, Axel Künstner, Michael Kohl, Tobias Barmwater, Helal Mohammed Ahmed, Almuth Caliebe, Eva Dazert-Klebsattel, Anke Fähnrich, Stephanie Fliedner, Niklas Gebauer, Malte Spielmann, Jutta Kirfel, Verena-Wilbeth Sailer, Lorenz Bastian, Nikolas Von Bubnoff, Hauke Busch, Cyrus Khandanpour

Blood (2023) 142 (Supplement 1): 5605.

https://doi.org/10.1182/blood-2023-184994

Published: 2023

Journal Articles

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Blood (2023) 141 (23): 2824–2840.

https://doi.org/10.1182/blood.2022015653

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser

Blood (2023) 141 (22): 2771–2779.

https://doi.org/10.1182/blood.2022018579

Published: 2023

Includes: Supplemental data

Journal Articles

Genome-Wide DNA Methylation Profiling in Blastic Plasmacytoid Dendritic Cell Neoplasm

Hanno M. Witte, Axel Künstner, Julian Schwarting, Veronica Bernard, Stephanie Stölting, Nikolas von Bubnoff, Eva Penas, Hartmut Merz, Reiner Siebert, Hauke Busch, Alfred Feller, Niklas Gebauer

Blood (2022) 140 (Supplement 1): 11496–11497.

https://doi.org/10.1182/blood-2022-162212

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

Journal Articles

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

Blood (2021) 138 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2021-150361

Published: 2021

Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137603

Published: 2020

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-135880

Published: 2020

Journal Articles

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Blood (2019) 134 (Supplement_1): 672.

https://doi.org/10.1182/blood-2019-127859

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Journal Articles

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Blood (2018) 132 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2018-99-115895

Published: 2018

Journal Articles

CCL5 Mediates Target-Kinase Independent Resistance to FLT3 Inhibitors in FLT3-ITD-Positive AML

Silvia Waldeck, MSc, Michael Rassner, MD, Philip Keye, MDstudent, Nikolas von Bubnoff, MD, Justus Duyster

Blood (2017) 130 (Supplement 1): 3830.

https://doi.org/10.1182/blood.V130.Suppl_1.3830.3830

Published: 2017

Journal Articles

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

Blood (2017) 130 (Supplement 1): 253.

https://doi.org/10.1182/blood.V130.Suppl_1.253.253

Published: 2017

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

NARROW

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)

Liquid Biopsy Enhances Diagnostic Workup of Hereditary Alpha-Tryptasemia (HaT) and Systemic Mastocytosis (SM) in Patients with Mast Cell-Mediated Symptoms and Elevated Basal Tryptase Levels

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Virtual Reality-Assisted Exercise Therapy during Inpatient Treatment after Intensive Chemotherapy for Acute Myeloid Leukemia (AML) and after Autologous or Allogeneic Stem Cell Transplantation

Mutational Changes in Solid Cancer Cells Induce DNA Damage Repair Deficiency in Hematopoietic Cells Leading to a Distinct Spectrum of Clonal Hematopoiesis Independent from Age-Related Clonal Hematopoiesis

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Genome-Wide DNA Methylation Profiling in Blastic Plasmacytoid Dendritic Cell Neoplasm

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

CCL5 Mediates Target-Kinase Independent Resistance to FLT3 Inhibitors in FLT3-ITD-Positive AML

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only